FGFR4 and hepatocellular carcinoma: Overall, our data indicated that the combination of FGFR4 and EZH2 inhibitors can significantly inhibit tumor growth both in vitro and in vivo, which would supply new literatures for the development of clinical treatment strategies for HCC.